Now is the time for shorter all-oral regimens for multidrug-resistant TB

The newly revised WHO guidelines for multidrug-resistant tuberculosis treatment includes major changes from the previous version, published in 2016. Notably, drugs such as bedaquiline, linezolid, and clofazimine are now strongly recommended for the treatment of multidrug-resistant tuberculosis. At the same time, older drugs, such as injectables, ethionamide, and para-aminosalicyclic acid, have been downgraded due to poor effectiveness and side-effect profiles. These new recommendations, if implemented, are expected to have a huge impact globally, increasing access of patients with multidrug-resistant tuberculosis to more effective and safer drug regimens that avoid debilitating side-effects, such as permanent hearing loss.

To read the full correspondence, published in The Lancet Global Health, click here.

To subscribe to the Weekly Newsletter of new posts, enter your email here:

By Kwonjune J Seung and Cathy Hewison

Published: April 21, 2019, 8:37 p.m.

Last updated: April 21, 2019, 9:48 p.m.

Print Share